Ormeloxifene: a better therapeutic option than Medroxyprogesterone Acetate in perimenopausal women with abnormal uterine bleeding.
Not Applicable
Not yet recruiting
- Conditions
- Health Condition 1: N920- Excessive and frequent menstruation with regular cycle
- Registration Number
- CTRI/2019/09/021275
- Lead Sponsor
- ivedita Chawla
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
All perimenopausal females between the age of 39 to 51 years with abnormal uterine bleeding.
Exclusion Criteria
a.Pregnancy
b.Organic Pelvic Pathology like polyp, fibroid, adenomyosis, endometriosis
c.Systemic Pathology
d.Coagulation disorders
e.Breast malignancy
f.Endometrial Hyperplasia with atypia
g.Endocrine disorders like hypothyroidism
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method